Circulating Tumor Cell Detection in Lung Cancer: But to What End?
The understanding of the natural history and biology of lung cancer has been enhanced by studies into circulating tumor cells (CTCs). Fundamental and translational research, as well as clinical trials in the characterization and behavior of these cells, have constantly contributed to improving under...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-02-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/11/2/262 |
id |
doaj-d030b8e165eb44ed92922988865cc76f |
---|---|
record_format |
Article |
spelling |
doaj-d030b8e165eb44ed92922988865cc76f2020-11-24T23:31:17ZengMDPI AGCancers2072-66942019-02-0111226210.3390/cancers11020262cancers11020262Circulating Tumor Cell Detection in Lung Cancer: But to What End?Véronique Hofman0Simon Heeke1Charles-Hugo Marquette2Marius Ilié3Paul Hofman4Laboratory of Clinical and Experimental Pathology, CHU Nice, FHU OncoAge, University Côte d’Azur, 06100 Nice, FranceLaboratory of Clinical and Experimental Pathology, CHU Nice, FHU OncoAge, University Côte d’Azur, 06100 Nice, FranceTeam 4, IRCAN, FHU OncoAge, University Côte d’Azur, CNRS, INSERM, 06107 Nice CEDEX 02, FranceLaboratory of Clinical and Experimental Pathology, CHU Nice, FHU OncoAge, University Côte d’Azur, 06100 Nice, FranceLaboratory of Clinical and Experimental Pathology, CHU Nice, FHU OncoAge, University Côte d’Azur, 06100 Nice, FranceThe understanding of the natural history and biology of lung cancer has been enhanced by studies into circulating tumor cells (CTCs). Fundamental and translational research, as well as clinical trials in the characterization and behavior of these cells, have constantly contributed to improving understanding within the domain of thoracic oncology. However, the use of these CTCs as prognostic and predictive biomarkers has not been adopted to the same extent as circulating free DNA (cf-DNA) in plasma, in the daily practice of thoracic oncologists. However, recent technological advances have firmly put the detection and characterization of CTCs in thoracic oncology back on the agenda, and have opened up perspectives for their routine clinical use. This review discusses the major advances of using CTCs in the domain of thoracic oncology, as well as the envisaged short- and long-term prospects.https://www.mdpi.com/2072-6694/11/2/262circulating tumor cellsliquid biopsylung cancerpersonal medicinetechniquesxenograft |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Véronique Hofman Simon Heeke Charles-Hugo Marquette Marius Ilié Paul Hofman |
spellingShingle |
Véronique Hofman Simon Heeke Charles-Hugo Marquette Marius Ilié Paul Hofman Circulating Tumor Cell Detection in Lung Cancer: But to What End? Cancers circulating tumor cells liquid biopsy lung cancer personal medicine techniques xenograft |
author_facet |
Véronique Hofman Simon Heeke Charles-Hugo Marquette Marius Ilié Paul Hofman |
author_sort |
Véronique Hofman |
title |
Circulating Tumor Cell Detection in Lung Cancer: But to What End? |
title_short |
Circulating Tumor Cell Detection in Lung Cancer: But to What End? |
title_full |
Circulating Tumor Cell Detection in Lung Cancer: But to What End? |
title_fullStr |
Circulating Tumor Cell Detection in Lung Cancer: But to What End? |
title_full_unstemmed |
Circulating Tumor Cell Detection in Lung Cancer: But to What End? |
title_sort |
circulating tumor cell detection in lung cancer: but to what end? |
publisher |
MDPI AG |
series |
Cancers |
issn |
2072-6694 |
publishDate |
2019-02-01 |
description |
The understanding of the natural history and biology of lung cancer has been enhanced by studies into circulating tumor cells (CTCs). Fundamental and translational research, as well as clinical trials in the characterization and behavior of these cells, have constantly contributed to improving understanding within the domain of thoracic oncology. However, the use of these CTCs as prognostic and predictive biomarkers has not been adopted to the same extent as circulating free DNA (cf-DNA) in plasma, in the daily practice of thoracic oncologists. However, recent technological advances have firmly put the detection and characterization of CTCs in thoracic oncology back on the agenda, and have opened up perspectives for their routine clinical use. This review discusses the major advances of using CTCs in the domain of thoracic oncology, as well as the envisaged short- and long-term prospects. |
topic |
circulating tumor cells liquid biopsy lung cancer personal medicine techniques xenograft |
url |
https://www.mdpi.com/2072-6694/11/2/262 |
work_keys_str_mv |
AT veroniquehofman circulatingtumorcelldetectioninlungcancerbuttowhatend AT simonheeke circulatingtumorcelldetectioninlungcancerbuttowhatend AT charleshugomarquette circulatingtumorcelldetectioninlungcancerbuttowhatend AT mariusilie circulatingtumorcelldetectioninlungcancerbuttowhatend AT paulhofman circulatingtumorcelldetectioninlungcancerbuttowhatend |
_version_ |
1725538603655757824 |